PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.70

0.0%

12:54 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (4216)	7/10/1998 6:40:00 PM
From: BigKNY3	Read Replies (1) of 9523

Jul 10, 1998 (6:17 PM ET) - The Motley Fool Evening News Erectile dysfunction treatment developer Vivus Inc. (Nasdaq:VVUS - news) fell $1 7/32 to $6 1/2 after reporting a second quarter loss of $0.55 a share (before charges) compared with earnings of $0.28 for the same year-ago period. Analysts had expected a loss of $0.45. Although Vivus shares rose on Pfizer's (NYSE:PFE - news) coattails, thanks to investors who thought the company would benefit from heightened interest in Pfizer's Viagra impotence pill, domestic demand for Vivus' MUSE product has dropped about 70% since the launch. Second quarter revenues totaled $16 million, down from $33.5 million in the year-earlier period and $26.5 million in Q1. There was a ray of sunshine abroad for Vivus, though. Revenues rose to $9.8 million from $2 million in the preceding quarter as the company's international marketing partners, Janssen Pharmaceutica and Astra AB (NYSE:A - news) , began launching MUSE in various countries. Of course, Viagra has yet to be approved for marketing globally, so Vivus hasn't had to face competition overseas.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next